Standardized SEC financial data for ADMA BIOLOGICS, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001368514 · NASDAQ · Biological Products, (No Diagnostic Substances).
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Cost of revenue | $61.3M | $79.8M | $118.8M | $169.3M | $206.9M | $217.4M |
| Gross profit | -$19.1M | $1.2M | $35.3M | $88.9M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $55.9M | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M |
| Inventory | $81.5M | $124.7M | $163.3M | $172.9M | $170.2M | $206.5M |
| Total current assets | $153.7M | $208.7M | $270.4M | $257.0M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$102.0M | -$112.4M | -$59.5M | $8.8M | $118.7M | $50.4M |
| Capital expenditures | $12.7M | $13.5M | $13.9M | $4.8M | $8.2M | $22.6M |
| Free cash flow | -$114.7M | -$125.9M | -$73.4M | $4.0M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/ADMA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/ADMA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $219.6M |
| $292.8M |
| R&D expense | $5.9M | $3.6M | $3.6M | $3.3M | $1.8M | $4.8M |
| SG&A expense | $35.1M | $42.9M | $52.5M | $59.0M | $74.1M | $91.6M |
| Operating income | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| EBITDA | -$61.0M | -$52.9M | -$32.3M | $30.0M | $147.0M | $199.5M |
| Interest expense | $12.0M | $13.1M | $19.3M | $25.0M | $10.7M | $9.1M |
| Pretax income | — | — | -$65.9M | -$28.2M | $125.7M | $182.7M |
| Income tax | $0 | $0 | $0 | $0 | $72.0M | $35.7M |
| Net income | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| EPS (diluted) | $-0.88 | $-0.51 | $-0.33 | $-0.13 | $0.81 | $0.60 |
Standardized from ADMA BIOLOGICS, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $331.4M |
| $466.5M |
| Property, plant & equipment | $41.6M | $50.9M | $58.3M | $53.8M | $54.7M | $65.1M |
| Goodwill | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Total assets | $207.7M | $276.3M | $348.5M | $329.2M | $488.7M | $624.2M |
| Total current liabilities | $19.9M | $30.4M | $39.3M | $49.8M | $55.5M | $69.5M |
| Long-term debt | — | — | — | — | $72.3M | $72.1M |
| Total debt | — | — | — | — | $72.3M | $75.0M |
| Total liabilities | $119.4M | $135.1M | $196.5M | $194.0M | $139.7M | $146.9M |
| Retained earnings | -$340.5M | -$412.1M | -$478.0M | -$506.3M | -$308.6M | -$161.7M |
| Total equity | $88.2M | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M |
| $110.4M |
| $27.8M |
| Investing cash flow | -$12.7M | -$13.5M | -$13.9M | -$5.0M | -$8.6M | -$21.9M |
| Financing cash flow | $143.9M | $121.0M | $108.9M | -$39.0M | -$58.3M | -$44.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | — | — | — | $0 | $0 | $31.9M |